Literature DB >> 9270029

Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.

J E Landers1, S L Cassel, D L George.   

Abstract

The mdm2 oncogene has transforming potential that is activated by overexpression. We previously reported the identification of human choriocarcinoma cell lines that have very high levels of mdm2 proteins as well as elevated levels of a stabilized wild-type p53 protein. Importantly, this mdm2 overexpression resulted from enhanced translation of mdm2 mRNA, a mechanism that had not previously been implicated in mdm2 expression control. The focus of this study was to investigate the breadth of enhanced translation of mdm2 mRNA in human cancers and to elucidate the basis for this translational activation. Here we present evidence that translational enhancement of mdm2 expression occurs in a variety of human tumor cells. Most of these samples also have high levels of wild-type p53 protein. However, there is no evidence for concomitant overexpression of the p53 target genes p21/waf1 and gadd45. Additionally, we demonstrate that the translational enhancement of mdm2 involves a preferential increase in mdm2 transcription that is initiated from the internal p53-responsive promoter region of this gene. The particular mdm2 transcripts that are generated contain a distinct 5' untranslated region and exhibit a significantly enhanced translational efficiency. These data provide a quantitative explanation for the overexpression of mdm2 proteins in this class of human tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9270029

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

Review 1.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

Review 2.  Upstream open reading frames as regulators of mRNA translation.

Authors:  D R Morris; A P Geballe
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer.

Authors:  R Ralhan; A Sandhya; M Meera; W Bohdan; S K Nootan
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 4.  Bugs as drugs for cancer.

Authors:  Eleanor J Cheadle; Andrew M Jackson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

5.  An essential role for the Saccharomyces cerevisiae DEAD-box helicase DHH1 in G1/S DNA-damage checkpoint recovery.

Authors:  Megan Bergkessel; Joseph C Reese
Journal:  Genetics       Date:  2004-05       Impact factor: 4.562

Review 6.  Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.

Authors:  Stian Knappskog; Per E Lønning
Journal:  Transcription       Date:  2011 Sep-Oct

7.  Coordination between cell cycle progression and cell fate decision by the p53 and E2F1 pathways in response to DNA damage.

Authors:  Xiao-Peng Zhang; Feng Liu; Wei Wang
Journal:  J Biol Chem       Date:  2010-08-04       Impact factor: 5.157

8.  MDMX regulation of p53 response to ribosomal stress.

Authors:  Daniele M Gilkes; Lihong Chen; Jiandong Chen
Journal:  EMBO J       Date:  2006-11-16       Impact factor: 11.598

Review 9.  Translational Control in Cancer.

Authors:  Nathaniel Robichaud; Nahum Sonenberg; Davide Ruggero; Robert J Schneider
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-07-01       Impact factor: 10.005

10.  Origin licensing and p53 status regulate Cdk2 activity during G(1).

Authors:  Kathleen R Nevis; Marila Cordeiro-Stone; Jeanette Gowen Cook
Journal:  Cell Cycle       Date:  2009-06-21       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.